Avicanna (AVCN) Status Update summary

Business model and strategic evolution

• Transitioned from pharmaceutical R&D to commercializing medical cannabis products, leveraging proprietary drug delivery systems and technologies.

• Operates four business pillars: RHO Phyto (medical products), MyMedi (medical cannabis care platform), pharmaceutical pipeline, and Aureus (API/raw materials division in Colombia).

• Asset-light model in Canada, licensing technology to 10 licensed producers and expanding through 15 commercial channels.

• International expansion includes exports to Europe and Australia, and collaborations in the US and South America.

• Strategic partnerships with Fortune 100/500 and leading cannabis companies, plus ongoing M&A exploration.

Product and R&D advancements

• Expanded commercial SKUs in Canada by 24% to 52, with increased listings and entry into new medical channels.

• RHO Phyto portfolio includes 30 proprietary SKUs, now with minor cannabinoids, and is supported by clinical trials and real-world evidence studies.

• Launched new patented technologies: deep tissue gel/spray, Influit (self-emulsifying system), and PwdRx (powder delivery), with promising preclinical results.

• Aureus division now produces GACP and organic certified flower, exporting to Switzerland and targeting Europe and Australia.

• Trunerox, a 10% CBD pharmaceutical for epilepsy, launched in Colombia, leveraging low-cost manufacturing.

Medical platform and clinical engagement

• MyMedi platform expanded, offering comprehensive patient support, insurance processing, and treatment planning.

• Enhanced educational initiatives, partnerships, and programs for prescribers, institutions, and patients.

• Hosted Avicanna Symposium with 400+ medical professionals, reinforcing leadership in cannabinoid research.

• Developed Morpheus patient intelligence platform for real-world data and treatment optimization.

• Advanced clinical studies: national real-world evidence study (450+ patients) and phase II RCT for osteoarthritic pain.